Anti-GPC3 CAR T

CAR T-cell therapy targeting Glypican-3 (GPC3) · CARsgen Therapeutics Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Anti-GPC3 CAR T, covering 2016-08-24 to 2017-03-20. Get the full timeline:

Most recent: Clinical Trial Update: Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]